New method to modulate the immune system for Type 1 diabetes
New approach for immune modulation against T1D
This study is testing a new treatment for Type 1 diabetes that aims to help your immune system work better by encouraging the growth of special cells that can protect your insulin-producing cells, using a unique delivery method to make it safe and effective for people with T1D.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evoq Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10931397 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy approach for Type 1 diabetes (T1D), an autoimmune condition that leads to the destruction of insulin-producing cells in the pancreas. The study aims to induce regulatory T cells (Tregs) that can help restore immune balance and prevent the progression of T1D. Researchers are utilizing synthetic high-density lipoprotein NanoDiscs designed to target lymph nodes and promote a robust Treg response. This innovative method seeks to provide a safe and effective treatment option for individuals suffering from T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 diabetes, particularly those experiencing challenges with current management strategies.
Not a fit: Patients with Type 1 diabetes who have already developed severe complications or those with other autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that helps manage or potentially reverse Type 1 diabetes.
How similar studies have performed: Previous research has shown promise in using immunotherapy approaches to modulate immune responses in autoimmune diseases, indicating potential for success with this novel method.
Where this research is happening
Ann Arbor, United States
- Evoq Therapeutics, INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Daniel, Weston — Evoq Therapeutics, INC.
- Study coordinator: Daniel, Weston
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.